Multiple Myeloma
Specialty Channel

Featured Article
The FDA has approved isatuximab-irfc plus carfilzomib and dexamethasone for the treatment of adults with relapsed/refractory MM given 1 to 3 previous lines of therapy.
The FDA approved idecabtagene vicleucel for the treatment of patients with multiple myeloma who have not responded to, or whose disease has returned after, at least 4 prior lines of therapy.
The FDA has approved melphalan flufenamide plus dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (MM).
True or False: Ixazomib, an oral proteasome inhibitor, is ideal for multiple myeloma treatment due to a history of low rates of polyneuropathy and patient tolerability.
At the virtual Great Debates & Updates in Hematologic Malignancies, Dr Mikhael presented emerging therapies in multiple myeloma (MM).
Available clinical data presented at the virtual 2020 ASH Annual meeting finds P-BCMA-101 CAR-T therapy, targeting BCMA, can produce significant efficacy with low toxicity in patients with relapsed/…
Data being presented at the virtual 62nd ASH Annual Meeting and Exposition show that triplet therapy is superior to doublet therapy for the treatment of lenalidomide-refractory MM.
True or False: Data suggest that teclistamab is a promising therapy for patients with BCMA-positive MM.
The 2 most common treatment regimens administered to patients with MM are an RvD-like regimen and the combination of daratumumab, lenalidomide, and __________.

News

The FDA has approved isatuximab-irfc plus carfilzomib and dexamethasone for the treatment of adults with relapsed/refractory MM given 1 to 3 previous lines of therapy.
The FDA approved idecabtagene vicleucel for the treatment of patients with multiple myeloma who have not responded to, or whose disease has returned after, at least 4 prior lines of therapy.
The FDA has approved melphalan flufenamide plus dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (MM).
At the virtual Great Debates & Updates in Hematologic Malignancies, Dr Mikhael presented emerging therapies in multiple myeloma (MM).

Interactive Features

True or False: Ixazomib, an oral proteasome inhibitor, is ideal for multiple myeloma treatment due to a history of low rates of polyneuropathy and patient tolerability.
True or False: Data suggest that teclistamab is a promising therapy for patients with BCMA-positive MM.
The 2 most common treatment regimens administered to patients with MM are an RvD-like regimen and the combination of daratumumab, lenalidomide, and __________.
True or False: Findings suggest that a correlation may exist between low education levels and poor survival in patients with multiple myeloma in China.
Stay in the know.
OncNet Newsletter